Searching Urinary Tumor Markers for Bladder Cancer Using a Two-Dimensional Differential Gel Electrophoresis (2D-DIGE) Approach

Orenes‐Piñero, Esteban; Cortón, Marta; González‐Peramato, Pilar; Algaba, Ferrán; Casal, J. Ignacio; Serrano, Álvaro; Sänchez‐Carbayo, Marta

doi:10.1021/pr070368w

Cited by 76 publications

(54 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This allows the satisfactory comparison of two samples, but the comparison of several different experiments remains a challenge. However, recently the first studies showing the use of 2D DIGE to compare the urinary proteomes of multiple healthy individuals and different disease states (40,41) were published. Another limitation is that it is impossible to study peptides (in general, peptides/proteins Ͻ10 kDa) by 2DE.…”

Section: De-ms-2de-msmentioning

confidence: 99%

“…One of the first studies using 2D DIGE for the analysis of the urinary proteome aimed to identify biomarkers of BCa (41). 2D DIGE was used to analyze seven different sets of patients and healthy controls yielding 12 clearly differentially expressed spots.…”

Section: Figmentioning

confidence: 99%

“…In the next step an immunoassay was developed to study Reg-1 expression in urine. In a prospective analysis on 80 individuals containing 32 BCa patients (stage Ta to T2), this Reg-1 immunoassay allowed discrimination between BCa patients and healthy controls with a specificity and sensitivity of 81.3 and 81.3%, respectively (41).…”

Section: Figmentioning

confidence: 99%

See 2 more Smart Citations

Urine in Clinical Proteomics

Decramer

Peredo

Breuil

et al. 2008

Molecular & Cellular Proteomics

391

295

View full text Add to dashboard Cite

Urine has become one of the most attractive biofluids in clinical proteomics as it can be obtained non-invasively in large quantities and is stable compared with other biofluids. The urinary proteome has been studied by almost any proteomics technology, but mass spectrometry-based urinary protein and peptide profiling has emerged as most suitable for clinical application. After a period of descriptive urinary proteomics the field is moving out of the discovery phase into an era of validation of urinary biomarkers in larger prospective studies. Although mainly due to the site of production of urine, the majority of these studies apply to the kidney and the urinary tract, but recent data show that analysis of the urinary proteome can also be highly informative on non-urogenital diseases and used in their classification. Despite this progress in urinary biomarker discovery, the contribution of urinary proteomics to the understanding of the pathophysiology of disease upon analysis of the urinary proteome is still modest mainly because of problems associated to sequence identification of the biomarkers. Until now, research has focused on the highly abundant urinary proteins and peptides, but analysis of the less abundant and naturally existing urinary proteins and peptides still remains a challenge. In conclusion, urine has evolved as one of the most attractive body fluids in clinical proteomics with potentially a rapid application in the clinic.

show abstract

Section: De-ms-2de-msmentioning

confidence: 99%

Section: Figmentioning

confidence: 99%

See 1 more Smart Citation

Urine in Clinical Proteomics

Decramer

Peredo

Breuil

et al. 2008

Molecular & Cellular Proteomics

391

295

View full text Add to dashboard Cite

show abstract

“…Even now it is used as a quantitative proteomic technology that can resolve hundreds to thousands of proteins in a single gel. To overcome the limitations of gel-to-gel reproducibility, differential gel electrophoresis (DIGE) has been established (83,117,122). In a DIGE experiment, up to three different samples can be analyzed on a single gel, each labeled with a different fluorescent cyanine dye (Cy2, Cy3, and Cy5).…”

Section: Comprehensive Protein Quantificationmentioning

confidence: 99%

Methods and approaches for the comprehensive characterization and quantification of cellular proteomes using mass spectrometry

Mirza

Olivier

2008

Physiological Genomics

View full text Add to dashboard Cite

show abstract

“…The advantage of 2D-DIGE vs. 2-DE is that 2D-DIGE allows defining a statistical significance threshold for the differences in protein expression between disease and control specimens (9). To date, the 2D-DIGE-MS/MS approach has been successfully used to study different types of cancers (10).…”

Section: Introductionmentioning

confidence: 99%

Quantitative proteomic study of human prostate cancer cells with different metastatic potentials

Wang

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. Metastatic dissemination is a feature of most cancers including prostate cancer (PCa), and is the main cause of treatment failure and mortality. The aim of the study is to explore the mechanisms of PCa metastasis and to search for potential prognostic markers using proteomics. Two-dimensional fluorescent differential gel electrophoresis (2D-DIGE) was used to quantify proteins in normal prostate epithelial cells, bone metastasis-derived PC-3 cells, and visceral metastasis-derived PC-3M cells. Metastatic potential was confirmed by flow cytometry, electron microscopy, proliferating cell nuclear antigen assay, and wound healing assay. Differential protein expression was compared between PCa cells with different metastatic potentials (LNcap, DU145, PC-3 and PC-3M) and normal prostate epithelial cells (RWPE-1). Selected candidate proteins in human prostate tissues were analyzed using GOA, UniProt and GeneCards analyses. Eighty-six proteins were differentially expressed between cell lines (>1.5-fold, P<0.05). Among them, twelve proteins were identified by MALDI-TOF-MS. One protein was upregulated in normal prostate epithelial cells, nine proteins were upregulated in PC-3, and two proteins were upregulated in PC-3M. Proteins were divided into five groups according to their functions. The SETDB1 protein was closely associated with the prognosis of PCa. Bioinformatics suggested that SETDB1 might promote PCa bone metastasis through the WNT pathway. In conclusion, SETDB1 might be associated with the development of bone metastases from PCa. Further study is necessary to assess its exact role in PCa. IntroductionProstate cancer (PCa) is the most common malignancy in males and the second cause of cancer-related death in the USA and Europe (1). The incidence and mortality of PCa are rapidly increasing in China because of changes in diet and aging of the population (2). The proportion of PCa diagnosed at its early stage has increased because of the widespread screening of serum prostate-specific antigen (PSA) in the last two decades (3). However, many patients still present metastases at diagnosis, and metastases are the first factor leading to death from PCa (4). Patients with metastases do not benefit from radical prostatectomy or radiotherapy (5,6). Therefore, novel treatment approaches are needed.Proteomics is a powerful and effective tool to evaluate protein profiles (7). Two-dimensional fluorescent differential

show abstract

Searching Urinary Tumor Markers for Bladder Cancer Using a Two-Dimensional Differential Gel Electrophoresis (2D-DIGE) Approach

Cited by 76 publications

References 22 publications

Urine in Clinical Proteomics

Urine in Clinical Proteomics

Methods and approaches for the comprehensive characterization and quantification of cellular proteomes using mass spectrometry

Quantitative proteomic study of human prostate cancer cells with different metastatic potentials

Contact Info

Product

Resources

About